Antibe Therapeutics (STU:4B70) Forward Dividend Yield %: 0.00% (As of Jul. 06, 2026)


STU:4B70 Antibe Therapeutics Inc STU:4B70
10 GF Score
Price €2.44
View Full Analysis

What is Antibe Therapeutics Forward Dividend Yield %?

Antibe Therapeutics STU:4B70 10 Forward Dividend Yield % is 0.00% as of Jul. 06, 2026. GuruFocus rates STU:4B70 with a GF Score™ of 10/100.

As of today (2026-07-06), the Forward Annual Dividend Yield of Antibe Therapeutics is 0.00%.

As of today (2026-07-06), the Trailing Annual Dividend Yield of Antibe Therapeutics is 0.00%.

STU:4B70's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.26
* Ranked among companies with meaningful Forward Dividend Yield % only.

Antibe Therapeutics's Dividends per Share for the three months ended in Dec. 2023 was €0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Antibe Therapeutics  (STU:4B70) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Antibe Therapeutics Forward Dividend Yield % Related Terms

STU:4B70 vs VRTX, REGN, SGEN: Forward Dividend Yield % Comparison

For the Biotechnology subindustry, Antibe Therapeutics's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Antibe Therapeutics Forward Dividend Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Antibe Therapeutics's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Antibe Therapeutics's Forward Dividend Yield % falls into.


STU:4B70
10GF Score
Antibe Therapeutics Inc STU:4B70
Forward Dividend Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Antibe Therapeutics Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

What does a Forward Dividend Yield % of 0.00% mean?
Antibe Therapeutics (STU:4B70) has a Forward Dividend Yield % of 0.00% as of Jul. 06, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Antibe Therapeutics and its competitors.
Is Antibe Therapeutics' Forward Dividend Yield % too high?
Antibe Therapeutics' current Forward Dividend Yield % is 0.00%. Overall, Antibe Therapeutics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Antibe Therapeutics' Forward Dividend Yield % compare to VRTX and REGN?
Antibe Therapeutics' Forward Dividend Yield % of 0.00% can be compared against companies in the Biotechnology industry. The industry median Forward Dividend Yield % is 1.26. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.26, based on 147 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Antibe Therapeutics and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Antibe Therapeutics's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Antibe Therapeutics stock overvalued right now?
Antibe Therapeutics (STU:4B70) has a current Forward Dividend Yield % of 0.00%. The current Forward Dividend Yield % is 0.00%. Antibe Therapeutics' overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Antibe Therapeutics (STU:4B70), the current Forward Dividend Yield % is 0.00% as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Antibe Therapeutics Business Description

Address 15 Prince Arthur Avenue, Toronto, ON, CAN, M5R 1B2
Antibe Therapeutics Inc is a clinical stage biotechnology company leveraging its proprietary hydrogen sulfide (H2S) platform to develop next-generation therapies to address inflammation arising from a wide range of medical conditions. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Antibe's drug, otenaproxesul, is in development for the treatment of acute and chronic pain. The company's second pipeline drug is a GI-sparing alternative to ketoprofen. The company's next target is inflammatory bowel disease (IBD), a condition long in need of safer, more effective therapies.
10GF Score

Get the complete analysis for STU:4B70

Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.44
Price